Jun 23, 2014
The Motley Fool
Better Buy: Isis Pharmaceuticals vs. Arrowhead Research
Earlier this year, clinical-stage biotechs fell in dramatic fashion, as investors turned toward bigger health-care names generating revenue from approved products.
Arrowhead Research Corp PT Raised to $30.00
The firm currently has a "buy" rating on the stock. Jefferies Group's target price suggests a potential upside of 95.19% from the company's current price.
Arrowhead Research Corporation Announces New Clinical Candidate...
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, today announced its next clinical candidate ARC-AAT, an RNAi therapeutic designed to treat liver disease associated with Alpha-1 antitrypsin deficiency .
Arrowhead Research joins with broad-market Russell 3000 Index
Arrowhead Research Corporation , a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes .
Arrowhead Research Set to Join Russell 3000 Index
Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization.